Solei Cannabis Brand Introduces New Approach to Wellness with New Product Lineup and Brand Refresh
January 12, 2023 07:00 ET
|
Tilray Brands, Inc.
TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, today unveiled a...
Ananda Professional Launches Full-Spectrum Cannabinoid Complex Featuring CBD + CBN
February 21, 2022 12:01 ET
|
Ananda Professional
GEORGETOWN, Ky., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Ananda Professional is expanding its clinically-backed product portfolio with with a focus on technical innovation for condition-specific outcomes....
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma
December 20, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
Wake Up on the Right Side of Bed with Sky Wellness
October 27, 2021 17:51 ET
|
Sky Wellness
PHOENIX, Oct. 27, 2021 (GLOBE NEWSWIRE) -- The collection of sleep assist CBD products by Sky Wellness is the perfect combination of CBD, CBN, and melatonin. CBN - the cannabinoid for sleep - has been...
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
September 30, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021
September 17, 2021 13:14 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
September 17, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Registration for the September 21, 2021 event now open VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
September 13, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Establishes leadership position in manufacturing and commercialization of rare cannabinoidsPositions InMed within large and growing consumer health and wellness cannabinoid marketsTransitions InMed...
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 12, 2021 12:00 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based...
Open Book Extracts Raises $11.5M Series B Funding Round to Accelerate Global Growth
June 02, 2021 07:00 ET
|
Open Book Extracts
ROXBORO, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Open Book Extracts (OBX), a Roxboro, NC-based leading ingredient manufacturer and product development house for the industry’s most innovative and...